Greg Bodulovic is an intellectual property lawyer with postgraduate qualifications in biotechnology. He has broad experience in both the contentious and non-contentious aspects of intellectual property law and advises on the regulation of therapeutic goods in Australia.
His experience includes patent infringement and revocation proceedings before the Federal Court of Australia and High Court of Australia, and patent opposition proceedings before the Australian Patent Office. Greg has also acted in design, trade mark and copyright infringement proceedings and implemented and managed successful intellectual property enforcement campaigns for rights owners.
His non-contentious experience includes advising on the intellectual property and technology aspects of large, multi-jurisdictional corporate transactions, including drafting and negotiating licence agreements and technology transfer agreements and facilitating technology transfer.
Greg also advises on complex regulatory issues relating to pharmaceuticals and medical devices, including the application of the Pharmaceutical Benefits Scheme and industry codes of practice.
- Acting for a multinational pharmaceutical company in three separate proceedings in the Federal Court of Australia against eight separate parties (including the Commonwealth of Australia) in respect of claims on undertakings as to damages ordered in return for injunctions preventing the launch of generic extended release venlafaxine products. These three cases, which involved a six week trial, are the first cases in Australia to address claims on undertakings as to damages in pharmaceutical patent litigation by generic pharmaceutical companies, their suppliers and the Commonwealth of Australia.
- Acting for a multinational pharmaceutical company in a successful application for preliminary discovery for information relating to the manufacture of a biosimilar product. This involved successfully resisting an application for special leave to appeal to the High Court of Australia. This proceeding is Australia's first biosimilar patent dispute.
- Acting for a global supplier of differentiated consumable and capital products in two separate patent infringement and revocation proceedings before the Federal Court of Australia.
Life sciences regulatory
- Advising a leading US-based disruptor in the orthodontic field, in relation to the establishment of its Australian operations, including advising on a broad range of regulatory matters relating to medical devices and marketing and advertising of medical devices.
- Advising a Fortune 500 medical device company on regulatory matters and overseeing a multinational regulatory project in over 20 countries.
- Advising a multinational pharmaceutical company on an ongoing basis in relation to the regulation of therapeutic goods and clinical trials in Australia.
- Advising a party to a USD 1.6 billion joint venture in Australia and Asia on intellectual property issues, including drafting and negotiating intellectual property licence agreements and overseeing intellectual property due diligence.
- Advising a United States food manufacturer on the intellectual property and technology transfer aspects of its acquisition of an Australian company with patented plant processing technology.
- Advising a leading contact lens research and development company on various intellectual property issues, including the licensing of the company's patents to manufacturers.
- Implementing, coordinating and managing a successful intellectual property enforcement campaign for the owner and exclusive licensee of patents, copyright and trade marks relating to health and lifestyle products against more than 100 importers and distributors of infringing products.
Regular contributor to DLA Piper’s life sciences page.